DNMR - NAT FRO and UBS among pre-market losers
2023-04-03 08:16:44 ET
- OncoSec Medical ( ONCS ) -62% clinical data of the KEYNOTE-695 trial assessing TAVO EP in combination with KEYTRUDA (pembrolizumab) in patients with advanced melanoma refractory to anti-PD-1 treatment.
- Ascendis Pharma ( ASND ) -38% after FDA finds 'deficiencies' in TransCon application.
- TORM ( TRMD ) -11% .
- Dare Bioscience ( DARE ) -9% .
- Palisade Bio ( PALI ) -8% .
- Frontline ( FRO ) -7% .
- Stratasys ( SSYS ) -5% after rejecting increased Nano Dimension offer.
- World Wrestling Entertainment ( WWE ) -6% announce deal to combine UFC, wrestling in new $21B company.
- Danimer Scientific ( DNMR ) -6% .
- Nordic American Tankers ( NAT ) -5% .
- DHT Holdings ( DHT ) -5% .
- UBS Group ( UBS ) -5% .
For further details see:
NAT, FRO and UBS among pre-market losers